Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock The VITAMINS Randomized Clinical Trial

Imagem de Miniatura
Arquivos
art_FUJII_Effect_of_Vitamin_C_Hydrcortisone_and_Thiamine_vs_2020.PDF.pdf (468.66 KB)
Citações na Scopus
340
Tipo de produção
article
Data de publicação
2020
Editora
AMER MEDICAL ASSOC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
FUJII, Tomoko
LUETHI, Nora
YOUNG, Paul J.
FREI, Daniel R.
EASTWOOD, Glenn M.
FRENCH, Craig J.
DEANE, Adam M.
SHEHABI, Yahya
Autor de Grupo de pesquisa
VITAMINS Trial Investigators
Editores
Coordenadores
Organizadores
Citação
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, v.323, n.5, p.423-431, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Importance It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock. Objective To determine whether the combination of vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, improves the duration of time alive and free of vasopressor administration in patients with septic shock. Design, Setting, and Participants Multicenter, open-label, randomized clinical trial conducted in 10 intensive care units in Australia, New Zealand, and Brazil that recruited 216 patients fulfilling the Sepsis-3 definition of septic shock. The first patient was enrolled on May 8, 2018, and the last on July 9, 2019. The final date of follow-up was October 6, 2019. Interventions Patients were randomized to the intervention group (n = 109), consisting of intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours), or to the control group (n = 107), consisting of intravenous hydrocortisone (50 mg every 6 hours) alone until shock resolution or up to 10 days. Main Outcomes and Measures The primary trial outcome was duration of time alive and free of vasopressor administration up to day 7. Ten secondary outcomes were prespecified, including 90-day mortality. Results Among 216 patients who were randomized, 211 provided consent and completed the primary outcome measurement (mean age, 61.7 years [SD, 15.0]; 133 men [63%]). Time alive and vasopressor free up to day 7 was 122.1 hours (interquartile range [IQR], 76.3-145.4 hours) in the intervention group and 124.6 hours (IQR, 82.1-147.0 hours) in the control group; the median of all paired differences was -0.6 hours (95% CI, -8.3 to 7.2 hours; P = .83). Of 10 prespecified secondary outcomes, 9 showed no statistically significant difference. Ninety-day mortality was 30/105 (28.6%) in the intervention group and 25/102 (24.5%) in the control group (hazard ratio, 1.18; 95% CI, 0.69-2.00). No serious adverse events were reported. Conclusions and Relevance In patients with septic shock, treatment with intravenous vitamin C, hydrocortisone, and thiamine, compared with intravenous hydrocortisone alone, did not significantly improve the duration of time alive and free of vasopressor administration over 7 days. The finding suggests that treatment with intravenous vitamin C, hydrocortisone, and thiamine does not lead to a more rapid resolution of septic shock compared with intravenous hydrocortisone alone.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/35421
Referências
  1. Annane D, 2018, NEW ENGL J MED, V378, P809, DOI 10.1056/NEJMoa1705716
  2. Bornstein SR, 2003, FASEB J, V17, P1928, DOI 10.1096/fj.02-1167fje
  3. Brant EB, 2019, JAMA-J AM MED ASSOC, V322, P1257, DOI 10.1001/jama.2019.11643
  4. Cossey LN, 2013, AM J KIDNEY DIS, V61, P1032, DOI 10.1053/j.ajkd.2013.01.025
  5. Donnino MW, 2016, CRIT CARE MED, V44, P360, DOI 10.1097/CCM.0000000000001572
  6. Donnino MW, 2010, J CRIT CARE, V25, P576, DOI 10.1016/j.jcrc.2010.03.003
  7. Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
  8. Fisher BJ, 2012, AM J PHYSIOL-LUNG C, V303, pL20, DOI 10.1152/ajplung.00300.2011
  9. Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC
  10. Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825
  11. Fowler AA, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-32
  12. Fujii T, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033458
  13. Fujii T, 2019, CRIT CARE RESUSC, V21, P152
  14. Fujii T, 2019, CRIT CARE RESUSC, V21, P119
  15. Hudson EP, 2019, CRIT CARE RESUSC, V21, P236
  16. Kawade N, 2018, J NUTR SCI VITAMINOL, V64, P404, DOI 10.3177/jnsv.64.404
  17. Khanna A, 2017, NEW ENGL J MED, V377, P419, DOI 10.1056/NEJMoa1704154
  18. Lamarche J, 2011, INT J NEPHROL, DOI 10.4061/2011/146927
  19. Lehmann EL, 1998, NONPARAMETRICS STAT
  20. Liu V, 2014, JAMA-J AM MED ASSOC, V312, P90, DOI 10.1001/jama.2014.5804
  21. Marik PE, 2017, CHEST, V151, P1229, DOI 10.1016/j.chest.2016.11.036
  22. Obeid JS, 2013, J BIOMED INFORM, V46, P259, DOI 10.1016/j.jbi.2012.10.006
  23. SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
  24. Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289
  25. Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
  26. Tyml K, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030049
  27. Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835
  28. Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156
  29. Woolum JA, 2018, CRIT CARE MED, V46, P1747, DOI [10.1097/ccm.0000000000003311, 10.1097/CCM.0000000000003311]

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/08